Akèy › Kansè Poumon ki pa ti selil › Texas › Houston
Etid klinik pou Kansè Poumon ki pa ti selil nan Houston, TX
145 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Houston Methodist Hospital, Houston
- Houston Methodist West Hospital, Houston
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Houston Methodist Cancer Center ( Site 0191), Houston
- MD Anderson Cancer Center ( Site 0150), Houston
- Memorial Hermann Cancer Center ( Site 0172), Houston
- ak 2 plis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Local Institution - 0095, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- MD Anderson Cancer Hospital, Houston
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- ALX Center 5, Houston
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Ap rekriteFaz 3
- The University of Texas-MD Anderson Cancer Center, Houston
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Ap rekriteFaz 3
- Kelsey-Seybold Clinic Main Campus, Houston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Houston
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Houston
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Texas Oncology - Gulf Coast, Houston
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
- The University of Texas MD Anderson Cancer Center, Houston
- ak 5 plis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Kelsey Research Foundation, Houston
- Kelsey-Seybold Clinic - North Houston Campus, Houston
- Texas Oncology - Gulf Coast, Houston
- ak 5 plis
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Oncology Consultants PA, Houston
- University of Texas MD Anderson Cancer Center, Houston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Houston
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas, MD Anderson Cancer Center- Interventional Radiology, Houston
- ak 3 plis
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
- Oncology Consultants Texas, Houston
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
Ap rekriteFaz 1/2
- UT MD Anderson, Houston
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
Ap rekrite
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- Southwest Oncology Associates, Houston
- Lumi Research, Houston
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Kelsey-Seybold Clinic, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
- Local Institution - 0517, Houston
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Houston
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Houston
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Oncology Consultants, P.A., Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- Next Oncology - Houston, Houston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Local Institution - 0025, Houston
An External Control Arm Study in Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Oncology Consultants, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- University of Texas M. D. Anderson Cancer Center, Houston
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2/3
- Houston Methodist Hospital /ID# 262722, Houston
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Ap rekriteFaz 2
- MD ANDERSON CANCER CENTER (Data Collection Only), Houston
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- MD Anderson Cancer Center - University of Texas, Houston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Ap rekriteFaz 3
- Oncology Consultants P.A. ( Site 0113), Houston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Lumi Research, Houston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas - MD Anderson Cancer Center, Houston
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Oncology Consultants Texas Medical Center, Houston
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- Memorial Hermann Cancer Center ( Site 0015), Houston
- Oncology Consultants P.A. ( Site 0124), Houston
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- M. D. Anderson Cancer Center, Houston
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- MDACC, Houston
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Ap rekriteFaz 1/2
- Oncology Consultants (OC) - Texas Medical Center - Cancer Center, Houston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Houston
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center ( Site 0009), Houston
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Ap rekriteEtid obsèvasyon
- The University of Texas MD Anderson Cancer Center ( Site 0009), Houston
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
Ap rekriteFaz 1
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- The University of Texas - M.D. Anderson Cancer Center, Houston
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- University of Texas M. D. Anderson Cancer Center, Houston
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT - Oncology - Houston, Houston
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
- MD Anderson Cancer Center, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Md Anderson Cancer Center, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Oncology Consultants, Houston
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Ap rekriteFaz 1
- Local Institution - 0049, Houston
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Houston, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Research Site, Houston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Houston Methodist Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Texas LLC - Houston, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- University of Texas, MD Anderson Cancer Center, Houston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Houston Methodist Neal Cancer Center, Houston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA12-0, Houston
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- MD Anderson, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ZW251 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas M. D. Anderson Cancer Center, Houston
- U.T. MD Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners
Ap rekriteVolontè an sante akeyi
- Memorial Hermann, Houston
- University of Texas MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
Ap rekriteVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Ap rekriteFaz 1
- Research Site, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Repositioning Immunotherapy in VetArans With Lung Cancer
Ap rekriteFaz 2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1/2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
Ap rekriteEtid obsèvasyon
- Oncology Consultants, Houston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Oncology Consultants, P.A., Houston
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Ap rekriteFaz 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Etid Kansè Poumon ki pa ti selil nan lòt vil
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan Houston
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.